Evidence map›Paper›PMID 29991745›Full record

ArticleCell death and differentiation2019

Correction to: EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors.

Polina Zjablovskaja, Miroslava Kardosova, Petr Danek, Pavla Angelisova, Touati Benoukraf, Alexander A Wurm, Tomas Kalina, Stephanie Sian, Martin Balastik, Ruud Delwel and 7 more

Open access · bronzeAbstract readPublished Erratum
In one paragraph

Article in Cell death and differentiation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Rare Variants in the DNA Repair Pathway and the Risk of Colorectal Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 6 countries.

Polina ZjablovskajaDepartment of Hemato-Oncology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague 142 20, Prague 4, Czech Republic.
Miroslava KardosovaDepartment of Hemato-Oncology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague 142 20, Prague 4, Czech Republic.
Petr DanekDepartment of Hemato-Oncology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague 142 20, Prague 4, Czech Republic.
Pavla AngelisovaDepartment of Molecular Immunology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague, 142 20, Czech Republic.
Touati BenoukrafCancer Science Institute, National University of Singapore, 14 Medical Drive, Singapore, 117599, Singapore.
Alexander A WurmDivision of Hematology and Oncology, Leipzig University Hospital, Leipzig, Germany.
Tomas KalinaChildhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, University Hospital Motol, V Uvalu 84, Praha, 150 06, Czech Republic.
Stephanie SianCancer Science Institute, National University of Singapore, 14 Medical Drive, Singapore, 117599, Singapore.
Martin BalastikDepartment of Molecular Neurobiology, Institute of Physiology of the ASCR, Videnska 1083, Prague, 142 20, Czech Republic.
Ruud DelwelDepartment of Hematology, Erasmus University Medical Center, Wytemaweg 80, Rotterdam, 3015 CN, The Netherlands.
Tomas BrdickaDepartment of Leukocyte Signalling, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague, 142 20, Czech Republic.
Daniel G TenenCancer Science Institute, National University of Singapore, 14 Medical Drive, Singapore, 117599, Singapore.
Gerhard BehreDivision of Hematology and Oncology, Leipzig University Hospital, Leipzig, Germany.
Fréderic FioreCentre d'Immunophénomique, Aix Marseille Université, Inserm, CNRS, Marseille, F-13288, France.
Bernard MalissenCentre d'Immunologie de Marseille-Luminy, Aix Marseille Université, Inserm, CNRS, Marseille, F-13288, France.
Vaclav HorejsiDepartment of Molecular Immunology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague, 142 20, Czech Republic.
Meritxell Alberich-JordaDepartment of Hemato-Oncology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague 142 20, Prague 4, Czech Republic. alberich@img.cas.cz.
Czech Academy of Sciences, Institute of Molecular Genetics · CZCentre National de la Recherche Scientifique · FRLeipzig University · DECharles University · CZCzech Academy of Sciences, Institute of Physiology · CZErasmus MC · NLHarvard Stem Cell Institute · USNational University Cancer Institute, Singapore · SGNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since publication of this article, the authors identified an error in the acknowledgments section. The original sentence in acknowledgments reads as follows.

Identifiers

PMID29991745
PMCPMC6294764
OpenAlexW2821256442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.